Callisto Pharmaceuticals Files Suit Against Tapestry Pharmaceuticals for Breach of Confidential Disclosure Agreement.

PR Newswire Europe, December, 2006

NEW YORK, December 21 /PRNewswire/ --

Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and other major health threats, announced today that it has filed a complaint against Tapestry Pharmaceuticals, Inc. (Nasdaq: TPPH), Leonard P. Shaykin and Kai P. Larson in the Supreme Court of the State of New York alleging that Tapestry used the information they obtained pursuant to a confidential disclosure agreement between the companies to cause Donald Picker, Ph.D., Callisto's Executive Vice President, Research & Development, to resign from Callisto and accept a position with Tapestry. In addition, Callisto is alleging that Tapestry fraudulently entered into the confidential disclosure agreement and...

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement